A groundbreaking trial explores personalized endocrine therapy for early-stage breast cancer, aiming to reduce chemotherapy's ...

The HIMALAYA study reveals the STRIDE regimen significantly improves 5-year survival rates in unresectable HCC, redefining ...

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted ...

Jacob Sands, MD, discusses anaging Dato-DXd toxicities like stomatitis, eye irritation, and interstitial lung disease, which ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Atossa Therapeutics advances Z-endoxifen for ER+/HER2- metastatic breast cancer, receiving FDA support for dose optimization ...

Bradley A. McGregor, MD, director of Clinical Research for the Lank Center of Genitourinary Oncology at the Dana-Farber Cancer Institute, discusses the advancements in treating metastatic renal cell ...

Panelists discuss how future research priorities include developing predictive biomarkers, exploring quadruple therapy ...

Cabozantinib and atezolizumab improve progression-free survival in metastatic prostate cancer, offering hope for high-risk patients despite no overall survival benefit.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Jacob Sands, MD, discusses the benefits of the arrival of Dato-DXd into the EGFR-positive non–small cell lung cancer treatment landscape and the next steps in research for this agent.